1、1As a supplement to our well-known quarterly Outlook report,Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2026.These drugs represent new drug classes,major changes to standards of care,and/or large market opportunities across the w

2、ide range of indications covered by Biomedtracker and Datamonitor Healthcare.This report will enable you to:Identify high-impact launches Discover drugs that could achieve blockbuster potential,transform treatment landscapes,or launch in new therapeutic classes.Anticipate competitive shifts Understa

3、nd which therapies may change the standard of care and disrupt existing markets.Track key regulatory milestones Follow critical catalysts,including PDUFA dates,pivotal trial readouts,and first approvals.Support strategic decisions Leverage our expert insights to enhance portfolio planning,competitor

4、s monitoring,and drive informed planning.Access concise analyst insights Benefit from clear,one-page summaries for each highlighted drug with therapy area,company details,likelihood of approval,and links to deeper analysis on BMT.Key Potential Drug Launches in 2026More details about each drug can be

5、 viewed on Biomedtracker by clicking the icon.CONTENTS PAGEBIOMEDTRACKER.COMKEY POTENTIAL DRUG LAUNCHES IN 2026(AS OF JULY 2025)A close up of a logoAI-generated content may be incorrect.2MethodologyScope and ObjectiveThis report highlights pharmaceutical candidates that were in Phase III or later st

6、ages of development as of July 2025,with select Phase IIb/II/III drugs included based on the presence of near-term regulatory catalysts.The primary objective is to identify drugs with significant potential for market impact(blockbuster potential),clinical relevance,and regulatory advancement.Strateg